Recently 188Re, a � � emitter, has started to be considered for medical use. Combining 99mTc, which is widely used in nuclear medicine, with 188Re opens up the possibility of developing related compounds for diagnostic imaging and therapy of a tumor site.Use of organometallic compounds of technetium or rhenium as tagging agents has received much study because they can be obtained in a clinically appropriate fashion and because compounds can be prepared that withstand biological nucleophiles and that target tumor sites.Diimines compounds of Re d6 with an appropriate sixth ligand are quite stable and can be modified for biological applications.  The most common diimines are 2,2'-bipyridine, and the Schiff base adducts pyridine-2-carbaldehyde imine, and diazabutadiene.Here we report the use of less common diimines:  2,2'-biimidazole, and 2-(2'-pyridyl)imidazole, 2-(2'-pyridyl)benzimidazole. Each of these ligands has the possibility of further modification by alkylation of an unbound amine. This could prove to be a way of attaching groups that could target a biological receptor.We have prepared nine Re(CO)3(N-N)X compounds using these three diimine ligands and X = Cl, Br, I. Each compound is completely characterized; the structures of five compounds were elucidated by single crystal X-ray crystallography. The three diimines, which have only occasionally been used in coordination complexes, bind tightly forming stable complexes.

Preparation of novel rhenium (I) compounds using less common diimine ligands

245th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.